Evidence review · Published July 22, 2026 · Sources checked July 22, 2026

Ipamorelin research overview

Ipamorelin is a synthetic pentapeptide developed as a growth-hormone secretagogue acting through a GHRP/ghrelin-receptor pathway rather than the GHRH receptor.

Evidence boundary: published research does not establish the identity or performance of a separately supplied batch. The catalog product is supplied only for qualified in vitro laboratory research and is not for human or animal use.

What is Ipamorelin?

The original pharmacology program used rat pituitary cells, rats, and swine. A separate dose-escalation study modeled pharmacokinetics and growth-hormone responses in healthy male volunteers.

Research category

Endocrine & receptor signaling

Study models represented

Pituitary cells, rats, swine, and a small human PK/PD study

Names in the literature

Growth-hormone secretagogue pentapeptide

Primary boundary

Acute endocrine responses do not establish therapeutic outcomes or general safety.

What does the selected evidence support?

Acute hormone measurements and animal selectivity experiments do not establish clinical benefit or long-term safety.

Primary sources

1. Raun et al., European Journal of Endocrinology (1998) — Discovery pharmacology in pituitary cells, rats, and swine. DOI: 10.1530/eje.0.1390552
2. Gobburu et al., Pharmaceutical Research (1999) — Dose-escalation pharmacokinetic/pharmacodynamic study in healthy volunteers. DOI: 10.1023/A:1018955126402

Research literature and product documentation are different

A publication describes a study and its results. A batch-specific Certificate of Analysis documents characteristics of a supplied research material. One does not substitute for the other.

Review Ipamorelin product specifications · Browse the COA library · Read the research-use policy

Prepared by The Pep Labs Research Editorial Team. This evidence summary is not medical advice and contains no dosing or administration guidance.